Da Silva Jorge Santos Sells 47,775 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos sold 47,775 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $20.03, for a total transaction of $956,933.25. Following the sale, the chief executive officer directly owned 2,877,118 shares of the company’s stock, valued at $57,628,673.54. This represents a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Da Silva Jorge Santos also recently made the following trade(s):

• On Monday, April 13th, Da Silva Jorge Santos sold 51,873 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $18.23, for a total transaction of $945,644.79.
• On Friday, April 10th, Da Silva Jorge Santos sold 98,127 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $18.41, for a total transaction of $1,806,518.07.

MoonLake Immunotherapeutics Price Performance

MLTX stock opened at $18.95 on Friday. MoonLake Immunotherapeutics has a 52-week low of $5.95 and a 52-week high of $62.75. The company’s 50 day simple moving average is $18.33 and its 200-day simple moving average is $17.04. The company has a debt-to-equity ratio of 0.39, a current ratio of 8.60 and a quick ratio of 8.60. The firm has a market capitalization of $1.39 billion, a P/E ratio of -4.90 and a beta of 1.04.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07). As a group, equities research analysts anticipate that MoonLake Immunotherapeutics will post -3.71 EPS for the current year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its stake in shares of MoonLake Immunotherapeutics by 3,343.2% in the first quarter. Millennium Management LLC now owns 344,320 shares of the company’s stock worth $13,453,000 after acquiring an additional 334,320 shares during the last quarter. Geode Capital Management LLC boosted its position in MoonLake Immunotherapeutics by 0.9% during the second quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock valued at $2,809,000 after purchasing an additional 559 shares during the last quarter. JPMorgan Chase & Co. grew its stake in MoonLake Immunotherapeutics by 4,584.5% in the second quarter. JPMorgan Chase & Co. now owns 39,397 shares of the company’s stock valued at $1,860,000 after purchasing an additional 38,556 shares in the last quarter. Legal & General Group Plc grew its stake in MoonLake Immunotherapeutics by 7.3% in the second quarter. Legal & General Group Plc now owns 20,905 shares of the company’s stock valued at $987,000 after purchasing an additional 1,425 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in MoonLake Immunotherapeutics in the 2nd quarter worth about $593,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on MLTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of MoonLake Immunotherapeutics in a research report on Monday, June 8th. Wolfe Research raised MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and increased their price objective for the stock from $12.00 to $24.00 in a research note on Monday, March 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 12th. BTIG Research restated a “buy” rating and set a $30.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 9th. Finally, Leerink Partners lifted their target price on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a research note on Wednesday. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of “Hold” and an average price target of $24.21.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.